Solvonis Therapeutics was granted its second US patent in a week covering compounds from its PTSD discovery programme (US patent number not specified). The consecutive patent grants strengthen IP protection around its CNS/PTSD pipeline and modestly de-risk the programme, which could support valuation upside despite no immediate clinical data, revenue or commercial milestones disclosed.
Solvonis Therapeutics was granted its second US patent in a week covering compounds from its PTSD discovery programme (US patent number not specified). The consecutive patent grants strengthen IP protection around its CNS/PTSD pipeline and modestly de-risk the programme, which could support valuation upside despite no immediate clinical data, revenue or commercial milestones disclosed.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
